Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib

Br J Haematol. 2019 Jun;185(5):944-947. doi: 10.1111/bjh.15645. Epub 2018 Nov 26.

¹ Department of Haematology & CBMT, Hospital of Bolzano, Bolzano, Italy.
² Internal Medicine V, Haematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria.
³ Fondazione Italiana LInfomi, Modena and Alessandria, Italy.
⁴ Hospital Pharmacy, Hospital of Bolzano, Bolzano, Italy.
⁵ Haematology, Santa Maria Nuova Hospital, IRCCS, Reggio Emilia, Italy.
⁶ ClinicaEmatologica e Unita' di TerapieCellulari "Carlo Melzi", Azienda Ospedaliera-Universitaria, Udine, Italy.
⁷ Padua University School of Medicine, Padova, Italy.
⁸ U.O. Ematologia, Ospedaledell'Angelo, Venezia-Mestre, Italy.
⁹ Transfusion Service, Haemophilia Centre and Haematology, Laboratory Analysis, Castelfranco Veneto Hospital, Castelfranco Veneto, Italy.
¹⁰ Department of Human Pathology, University of Messina, Messina, Italy.
¹¹ Department of Biological and Environmental Sciences, University of Messina, Messina, Italy.
¹² Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
¹³ Humanitas/Gavazzeni Cancer Center, Bergamo, Italy.

No abstract available

Keywords: bendamustine; dexametasone; myeloma; refractory; thalidomide.

Publication types